Tacrolimus trough levels were generally lower in patients receiving IL-2 RA as induction agent compared to patients receiving ATG, albeit only being significantly different at 180 days post-transplant (10.8 ± 4.5μg/mL for patients in the ATG group and 7.5 ± 2.4μg/mL for patients in the IL-2 RA group, P=0.002; Table 3). This evidence concerns the gene IL2 and rheumatoid arthritis.